StreetInsider.com News Articles

The Precision Peptide Company Opens Nationwide Retail Sales Days After FDA Panel Backs Six of Seven Peptides Under Review

Thu, 30 Jul 2026 07:00:00 -0400

Highlights

Seven products are now in stock and available to purchase at precisionpeptidecompany.com: BPC, KPV, Ageless, Chill, Blue, Hair and The Recovery Patch
The Recovery Patch is the Company's first transdermal peptide product available at retail, providing a needle-free format that requires no mixing, no measuring and no cold storage
All 50 U.S. states can order through the platform
LegitScript Healthcare Merchant Certification supports compliance, consumer-safety, payment-processing and advertising standards
GLP-1, Sermorelin and NAD+ protocols are listed on the platform as coming soon, supported by the Company's previously announced 503A compounding agreement and telehealth infrastructure
On July 23 and 24, 2026, the FDA's Pharmacy Compounding

The Precision Peptide Company Opens Nationwide Retail Sales Days After FDA Panel Backs Six of Seven Peptides Under Review

Thu, 30 Jul 2026 07:00:00 -0400

Highlights

Seven products are now in stock and available to purchase at precisionpeptidecompany.com: BPC, KPV, Ageless, Chill, Blue, Hair and The Recovery Patch
The Recovery Patch is the Company's first transdermal peptide product available at retail, providing a needle-free format that requires no mixing, no measuring and no cold storage
All 50 U.S. states can order through the platform
LegitScript Healthcare Merchant Certification supports compliance, consumer-safety, payment-processing and advertising standards
GLP-1, Sermorelin and NAD+ protocols are listed on the platform as coming soon, supported by the Company's previously announced 503A compounding agreement and telehealth infrastructure
On July 23 and 24, 2026, the FDA's Pharmacy Compounding

The Precision Peptide Company Advances First-to-Market Thymosin Alpha-1 Patch for Immune Support

Tue, 28 Jul 2026 07:00:00 -0400

Highlights

Q3/Q4 2026 is the targeted completion period for testing of The Precision Peptide Company's Thymosin Alpha-1 transdermal patch
2025 research continues to evaluate Thymosin Alpha-1 for immune regulation and inflammation, supporting its ongoing relevance within the peptide and immune-health landscape¹
The patch is being developed to bring Thymosin Alpha-1 into a portable, needle-free format without mixing or cold storage
Based on its review of currently publicly available products, The Precision Peptide Company believes the product could be among the first commercially available Thymosin Alpha-1 transdermal patches
Testing will evaluate formulation stability and performance within the transdermal patch format
The program expands the transdermal portfolio into

The Precision Peptide Company Advances First-to-Market Thymosin Alpha-1 Patch for Immune Support

Tue, 28 Jul 2026 07:00:00 -0400

Highlights

Q3/Q4 2026 is the targeted completion period for testing of The Precision Peptide Company's Thymosin Alpha-1 transdermal patch
2025 research continues to evaluate Thymosin Alpha-1 for immune regulation and inflammation, supporting its ongoing relevance within the peptide and immune-health landscape¹
The patch is being developed to bring Thymosin Alpha-1 into a portable, needle-free format without mixing or cold storage
Based on its review of currently publicly available products, The Precision Peptide Company believes the product could be among the first commercially available Thymosin Alpha-1 transdermal patches
Testing will evaluate formulation stability and performance within the transdermal patch format
The program expands the transdermal portfolio into

The Precision Peptide Company Applauds FDA Advisory Committee Vote on Expanded Pathway for BPC-157 and KPV

Fri, 24 Jul 2026 07:00:00 -0400

On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend BPC-157 for inclusion on the Section 503A Bulks List.
BPC-157 was the first of seven peptides considered at the July 23-24 meeting.
The Company markets a commercial portfolio of peptide products including KPV capsules and a BPC-157 transdermal patch.
As per the Company's news release dated July 14, 2026, the Company received a 20,000-unit production run of its BPC-157 transdermal patch.

Vancouver, British Columbia--(Newsfile Corp. - July 24, 2026) - The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on

The Precision Peptide Company Applauds FDA Advisory Committee Vote on Expanded Pathway for BPC-157 and KPV

Fri, 24 Jul 2026 07:00:00 -0400

On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend BPC-157 for inclusion on the Section 503A Bulks List.
BPC-157 was the first of seven peptides considered at the July 23-24 meeting.
The Company markets a commercial portfolio of peptide products including KPV capsules and a BPC-157 transdermal patch.
As per the Company's news release dated July 14, 2026, the Company received a 20,000-unit production run of its BPC-157 transdermal patch.

The Precision Peptide Company Activates Nationwide Direct-to-Consumer Peptide Sales with Retail Telehealth Website Launch

Tue, 21 Jul 2026 07:00:00 -0400

Highlights

The Precision Peptide Company's newly launched direct-to-consumer and telehealth platform is now available in all 50 states of the United States.
100% U.S.-compounded peptide products are supported through a 503A compounding agreement
July 23, 2026 is the scheduled FDA advisory committee review date for several peptide substances, including BPC-157; The Precision Peptide Company's compounding, telehealth, compliance and consumer-sales infrastructure is currently in place
The website brings together oral supplements, transdermal patches, topical products and telehealth services through one consumer-facing platform
The transdermal patches provide a differentiated, needle-free format that requires no mixing or cold storage
LegitScript Healthcare Merchant Certification supports compliance, consumer-safety, payment-processing and advertising

The Precision Peptide Company Activates Nationwide Direct-to-Consumer Peptide Sales with Retail Telehealth Website Launch

Tue, 21 Jul 2026 07:00:00 -0400

Highlights

The Precision Peptide Company's newly launched direct-to-consumer and telehealth platform is now available in all 50 states of the United States.
100% U.S.-compounded peptide products are supported through a 503A compounding agreement
July 23, 2026 is the scheduled FDA advisory committee review date for several peptide substances, including BPC-157; The Precision Peptide Company's compounding, telehealth, compliance and consumer-sales infrastructure is currently in place
The website brings together oral supplements, transdermal patches, topical products and telehealth services through one consumer-facing platform
The transdermal patches provide a differentiated, needle-free format that requires no mixing or cold storage
LegitScript Healthcare Merchant Certification supports compliance, consumer-safety, payment-processing and advertising

Precision Peptide closes $2M private placement of common shares

Wed, 15 Jul 2026 07:02:22 -0400

The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) has closed a non-brokered private placement of common shares, raising gross proceeds of $2,000,000 through the issuance of 4,000,000 shares at $0.50 per share.

The offering was conducted under the Listed Issuer Financing Exemption pursuant to Part 5A of National Instrument 45-106 - Prospectus Exemptions, and was available to purchasers resident in all Canadian provinces except Quebec. The securities issued are not subject to a hold period under applicable Canadian securities laws. No finder's fees were paid in connection with the transaction.

The company stated it intends to use the net proceeds for general

The Precision Peptide Company Inc. Announces Closing of LIFE Offering of Common Shares

Wed, 15 Jul 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - July 15, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), is pleased to announce that further to its news release dated June 11, 2026, it has closed its previously announced non-brokered private placement of common shares in the capital of the Company (the "Shares") at a price of $0.50 per Share under the Listed Issuer Financing Exemption (as defined herein) for gross proceeds of $2,000,000 (the "LIFE Offering") through the issuance of 4,000,000 Shares.

Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 - Prospectus

The Precision Peptide Company Inc. Announces Closing of LIFE Offering of Common Shares

Wed, 15 Jul 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - July 15, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), is pleased to announce that further to its news release dated June 11, 2026, it has closed its previously announced non-brokered private placement of common shares in the capital of the Company (the "Shares") at a price of $0.50 per Share under the Listed Issuer Financing Exemption (as defined herein) for gross proceeds of $2,000,000 (the "LIFE Offering") through the issuance of 4,000,000 Shares.
Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 - Prospectus

The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches

Tue, 14 Jul 2026 07:00:00 -0400

Highlights
Received full production run of approximately 20,000 BPC-157 transdermal patches, the Company's lead product candidate
Patches are manufactured and independently tested in the United States
Marks the Company's transition from testing to commercialization
Each patch delivers 2 mg of BPC-157, consistent with the 95.5% purity and 2.02 mg dose
Vancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has received its production run of approximately 20,000 units of its BPC-157 transdermal patch (the "Patch"),

The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches

Tue, 14 Jul 2026 07:00:00 -0400

Highlights
Received full production run of approximately 20,000 BPC-157 transdermal patches, the Company's lead product candidate
Patches are manufactured and independently tested in the United States
Marks the Company's transition from testing to commercialization
Each patch delivers 2 mg of BPC-157, consistent with the 95.5% purity and 2.02 mg dose
Vancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has received its production run of approximately 20,000 units of its BPC-157 transdermal patch (the "Patch"),

The Precision Peptide Company Activates Nationwide Direct-to-Consumer Peptide Sales with Retail Telehealth Website Launch

Tue, 07 Jul 2026 14:43:00 -0400

Highlights
The Precision Peptide Company can now sell its peptide products directly to consumers online across all 50 U.S. states, with its consumer-facing retail telehealth website now live
The site connects consumers with licensed providers, prescription workflows, and U.S.-based pharmacy fulfillment, bringing the Company's U.S. access pathway online
All peptides — including BPC-157 — will be 100% compounded in the United States under the Company's 503A compounding agreement
The Company's compliance and consumer-safety standards are independently validated through its LegitScript Healthcare Merchant Certification, and its platform is built to align with applicable U.S. legal, HIPAA, and pharmacy regulations
The launch expands retail and brand visibility as the

The Precision Peptide Company Activates Nationwide Direct-to-Consumer Peptide Sales with Retail Telehealth Website Launch

Tue, 07 Jul 2026 14:43:00 -0400

Highlights
The Precision Peptide Company can now sell its peptide products directly to consumers online across all 50 U.S. states, with its consumer-facing retail telehealth website now live
The site connects consumers with licensed providers, prescription workflows, and U.S.-based pharmacy fulfillment, bringing the Company's U.S. access pathway online
All peptides — including BPC-157 — will be 100% compounded in the United States under the Company's 503A compounding agreement
The Company's compliance and consumer-safety standards are independently validated through its LegitScript Healthcare Merchant Certification, and its platform is built to align with applicable U.S. legal, HIPAA, and pharmacy regulations
The launch expands retail and brand visibility as the

The Precision Peptide Company's Needle-Free Recovery Patch Featured in Men's Health Magazine

Tue, 30 Jun 2026 07:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 30, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that its needle-free Recovery Patch, formulated with BPC-157 peptide, will be featured in the June-August 2026 issue of Men's Health magazine.
The placement appears in the magazine's "Going Strong" product showcase, alongside a curated selection of premium men's health, performance, and longevity products. Men's Health is one of the largest mainstream consumer health publications in North America, reaching a broad readership across the performance, recovery,

The Precision Peptide Company's Needle-Free Recovery Patch Featured in Men's Health Magazine

Tue, 30 Jun 2026 07:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 30, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that its needle-free Recovery Patch, formulated with BPC-157 peptide, will be featured in the June-August 2026 issue of Men's Health magazine.
The placement appears in the magazine's "Going Strong" product showcase, alongside a curated selection of premium men's health, performance, and longevity products. Men's Health is one of the largest mainstream consumer health publications in North America, reaching a broad readership across the performance, recovery,

The Precision Peptide Company Achieves LegitScript Healthcare Merchant Certification

Tue, 23 Jun 2026 07:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations, today announced it has been awarded LegitScript Healthcare Merchant Certification - an independent, third-party seal recognizing the Company's compliance, transparency, and consumer-safety standards.
The certification is recognized by Visa, Mastercard, Google, Microsoft, and Meta, many of which require it before a healthcare business can process payments or advertise on their platforms. For the Company, it unlocks broader access to these payment and advertising channels and strengthens its e-commerce growth strategy.
Pratap

The Precision Peptide Company Achieves LegitScript Healthcare Merchant Certification

Tue, 23 Jun 2026 07:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations, today announced it has been awarded LegitScript Healthcare Merchant Certification - an independent, third-party seal recognizing the Company's compliance, transparency, and consumer-safety standards.
The certification is recognized by Visa, Mastercard, Google, Microsoft, and Meta, many of which require it before a healthcare business can process payments or advertise on their platforms. For the Company, it unlocks broader access to these payment and advertising channels and strengthens its e-commerce growth strategy.
Pratap

The Precision Peptide Company Announces Release of The Human Upgrade with Dave Asprey Episode Featuring Chief Scientific Officer Justin Kirkland

Tue, 16 Jun 2026 07:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 16, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that the previously announced episode of The Human Upgrade with Dave Asprey featuring Justin Kirkland, Chief Scientific Officer of the Company, is now available.
The episode is live on Apple Podcasts, Spotify, YouTube, and at daveasprey.com. The Human Upgrade, hosted by Dave Asprey, is a leading platform in the biohacking, longevity, and human performance space, built over more than a decade

The Precision Peptide Company Announces Release of The Human Upgrade with Dave Asprey Episode Featuring Chief Scientific Officer Justin Kirkland

Tue, 16 Jun 2026 07:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 16, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that the previously announced episode of The Human Upgrade with Dave Asprey featuring Justin Kirkland, Chief Scientific Officer of the Company, is now available.
The episode is live on Apple Podcasts, Spotify, YouTube, and at daveasprey.com. The Human Upgrade, hosted by Dave Asprey, is a leading platform in the biohacking, longevity, and human performance space, built over more than a decade

Precision Peptide Company plans up to $2 million private placement

Thu, 11 Jun 2026 17:02:10 -0400

The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) announced plans to raise between $1.5 million and $2 million through a private placement of common shares. The Vancouver-based wellness company intends to issue between 3 million and 4 million shares at $0.50 per share.

The offering will be conducted under Canada's listed issuer financing exemption and is available to residents of all Canadian provinces except Quebec. Shares issued under this exemption will not be subject to a hold period under Canadian securities laws.

The company stated it will use net proceeds for general working capital, advancing business objectives, funding marketing initiatives, and

The Precision Peptide Company Inc. Announces up to $2 Million LIFE Offering of Common Shares

Thu, 11 Jun 2026 17:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 11, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC") is pleased to announce that it intends to undertake a non-brokered private placement of a minimum of 3,000,000 and up to 4,000,000 common shares in the capital of the Company (the "Shares") at a price of $0.50 per Share for minimum gross proceeds of $1,500,000 and up to $2,000,000 (the "Offering").
The Offering is being completed pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 - Prospectus Exemptions, as amended by Coordinated Blanket Order 45-935

The Precision Peptide Company Inc. Announces up to $2 Million LIFE Offering of Common Shares

Thu, 11 Jun 2026 17:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 11, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC") is pleased to announce that it intends to undertake a non-brokered private placement of a minimum of 3,000,000 and up to 4,000,000 common shares in the capital of the Company (the "Shares") at a price of $0.50 per Share for minimum gross proceeds of $1,500,000 and up to $2,000,000 (the "Offering").
The Offering is being completed pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 - Prospectus Exemptions, as amended by Coordinated Blanket Order 45-935

The Precision Peptide Company Establishes Compliant U.S. Peptide Access with Telehealth and Prescription Infrastructure Partnership

Tue, 09 Jun 2026 07:30:00 -0400

Highlights
Signed an agreement with a U.S.-based prescription telehealth and infrastructure partner to support compliant prescribing, fulfillment, and delivery of the Company's peptide products
Builds on the Company's recently announced 503A compounding agreement, under which all peptides -including BPC-157- are to be 100% compounded in the United States
Partner platform is trusted by more than 100 telehealth brands and is designed to align with U.S. legal, HIPAA, and pharmacy regulations
Connects licensed provider networks across all 50 U.S. states with prescription and pharmacy fulfillment workflows
Supports a compliant, nationwide U.S. infrastructure for prescription-based peptide access ahead of anticipated U.S. regulatory developments
Vancouver, British Columbia--(Newsfile Corp. -